Can organophosphate cholinesterase inhibition overlap with donepezil's cholinergic effects?

Donepezil is an established acetylcholinesterase (AChE) inhibitor. In the setting of organophosphate-related cholinesterase inhibition, the two exposures have a biologically credible potential to converge on excessive acetylcholine signaling.

Clinical and pharmacodynamic evidence

• Donepezil produces clinically meaningful, concentration-dependent AChE inhibition. In healthy volunteers, erythrocyte AChE inhibition reached approximately 33–35% after single 4–6 mg doses and persisted for up to 72 hours; at usual 5–10 mg/day dosing, inhibition was approximately 64–78%.
• Its recognized cholinergic adverse effects include nausea, vomiting, diarrhea, anorexia/weight loss, dizziness, and fatigue. It may also increase vagal tone, with potential bradycardia, heart block, or syncope, including in people without known conduction disease.

Mechanistic and clinical implications of organophosphate exposure

• Organophosphates also inhibit AChE; therefore, organophosphate-related inhibition and donepezil can plausibly add to cholinergic burden.
• Clinically important organophosphate toxicity may involve muscarinic findings—excessive secretions, bronchospasm, and respiratory compromise—as well as nicotinic fasciculations and weakness and central nervous system manifestations. Donepezil could plausibly contribute particularly to gastrointestinal or vagal/cardiac cholinergic effects in this setting.
• The actual magnitude and timing of any added effect from donepezil are not established at the individual-patient level. Nonetheless, suspected organophosphate poisoning requires urgent syndrome-based evaluation, especially when respiratory symptoms, marked secretions, weakness, or altered mental status are present.

Practical considerations

• Red-cell AChE and plasma butyrylcholinesterase may support assessment, but should be interpreted alongside the clinical syndrome; urinary diethylthiophosphate indicates exposure rather than toxicity severity.
• Acute management centers on prompt atropine titrated to respiratory and muscarinic improvement; oxime therapy may be considered early in significant poisoning, particularly with weakness or respiratory compromise.

Bottom line

• Donepezil’s AChE inhibition is well established, and overlapping cholinergic effects during organophosphate-related cholinesterase inhibition are biologically plausible; clinical urgency should be driven by respiratory, neuromuscular, and muscarinic toxicity.